Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.57 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725741 | 1.00 | HDAC1 (0.57) | HDAC1HDAC2HDAC6BACE1HDAC3 | |
| SCHEMBL727347 | 0.89 | HDAC1 (0.48) | HDAC1HDAC2HDAC6POLB | |
| SCHEMBL727344 | 0.89 | HDAC1 (0.48) | HDAC1HDAC2HDAC6POLB | |
| SCHEMBL725021 | 0.86 | HDAC1 (0.44) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL725024 | 0.86 | HDAC1 (0.44) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL725502 | 0.84 | HDAC1 (0.42) | HDAC1HDAC2HDAC6POLB | |
| SCHEMBL725499 | 0.84 | HDAC1 (0.42) | HDAC1HDAC2HDAC6POLB | |
| SCHEMBL4479886 | 0.79 | HDAC1 (0.51) | HDAC1HDAC2HDAC6BACE1HDAC3 | |
| SCHEMBL4479873 | 0.79 | HDAC1 (0.51) | HDAC1HDAC2HDAC6BACE1HDAC3 | |
| SCHEMBL727134 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4803935-B2 | — | — | 2011-10-26 | — | — | JP | claimed |
| US-6846819-B1 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-01-25 | — | — | US | claimed |
| EP-1226138-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-12-29 | — | — | EP | claimed |
| EP-1226138-A4 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | claimed |
| EP-1226138-A1 | FAB I INHIBITORS | SmithKline Beecham Corporation (US) | 2002-07-31 | — | — | EP | claimed |
| WO-2001027103-A1 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORPORATION (GB) | 2001-04-19 | — | — | WO | claimed |
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | DEBIOPHARM INTERNATIONAL SA (CH) | 2013-10-24 | — | — | US | disclosed |
| EP-2579863-A2 | COMPOUNDS FOR TREATMENT OF BOVINE MASTITIS | Affinium Pharmaceuticals, Inc. (CA) | 2013-04-17 | — | — | EP | disclosed |
| US-8173646-B2 | FAB I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| WO-2011156811-A2 | COMPOUNDS FOR TREATMENT OF BOVINE MASTITIS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-12-15 | — | — | WO | disclosed |
| US-20110190283-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2011-08-04 | — | — | US | disclosed |
| US-7790716-B2 | fatty acid biosynthesis inhibitors such as E)-3-(6-aminopyridin-3-yl)-N-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)acrylamide, used fro the treatment of bacterial infections; antibiotics | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20090275572-A1 | FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7557125-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2009-07-07 | — | — | US | disclosed |
| US-20050250810-A1 | FAB I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-11-10 | — | — | US | disclosed |
| EP-1226138-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250810-A1 | FAB I inhibitors | SERPINB1, TFPI, TFPI2 | HDAC1 87/4885HDAC2 806/4885HDAC6 356/4885 |
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | LPO, MPO, MMP8 | HDAC1 488/4885HDAC2 638/4885HDAC6 363/4885 |
| US-20090275572-A1 | FAB I INHIBITORS | SERPINB1, TFPI, TFPI2 | HDAC1 87/4885HDAC2 806/4885HDAC6 356/4885 |
| US-20110190283-A1 | Fab I Inhibitors | SERPINB1, TFPI, TFPI2 | HDAC1 87/4885HDAC2 806/4885HDAC6 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.